BIOHAVEN PHARMACEUTICAL HOLDING CO LTD
NYSE: BHVN (Biohaven Ltd.)
Kemas kini terakhir: 12 jam lalu36.26
0.92 (2.60%)
| Penutupan Terdahulu | 35.34 |
| Buka | 34.85 |
| Jumlah Dagangan | 2,580,291 |
| Purata Dagangan (3B) | 1,079,892 |
| Modal Pasaran | 3,666,683,648 |
| Harga / Buku (P/B) | 11.75 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 3 Aug 2023 - 7 Aug 2023 |
| EPS Cair (TTM) | -9.37 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 8.01% |
| Nisbah Semasa (MRQ) | 2.89 |
| Aliran Tunai Operasi (OCF TTM) | -526.59 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -397.26 M |
| Pulangan Atas Aset (ROA TTM) | -118.79% |
| Pulangan Atas Ekuiti (ROE TTM) | -265.45% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Biohaven Ltd. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 4.5 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -0.5 |
| Purata | 2.50 |
|
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 11.16% |
| % Dimiliki oleh Institusi | 87.14% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Suvretta Capital Management, Llc | 30 Sep 2024 | 5,199,219 |
| Bellevue Group Ag | 30 Sep 2024 | 2,040,853 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 76.00 (Piper Sandler, 109.60%) | Beli |
| Median | 62.00 (70.99%) | |
| Rendah | 59.00 (HC Wainwright & Co., 62.71%) | Beli |
| Purata | 65.22 (79.87%) | |
| Jumlah | 9 Beli | |
| Harga Purata @ Panggilan | 45.42 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 17 Dec 2024 | 59.00 (62.71%) | Beli | 39.12 |
| 26 Nov 2024 | 59.00 (62.71%) | Beli | 47.28 | |
| RBC Capital | 04 Dec 2024 | 61.00 (68.23%) | Beli | 46.06 |
| 25 Nov 2024 | 58.00 (59.96%) | Beli | 45.23 | |
| TD Cowen | 13 Nov 2024 | 75.00 (106.84%) | Beli | 49.04 |
| JP Morgan | 03 Oct 2024 | 68.00 (87.53%) | Beli | 46.65 |
| B of A Securities | 24 Sep 2024 | 62.00 (70.99%) | Beli | 45.04 |
| Bernstein | 24 Sep 2024 | 66.00 (82.02%) | Beli | 45.04 |
| Baird | 23 Sep 2024 | 60.00 (65.47%) | Beli | 45.94 |
| Leerink Partners | 23 Sep 2024 | 60.00 (65.47%) | Beli | 45.94 |
| Piper Sandler | 23 Sep 2024 | 76.00 (109.60%) | Beli | 45.94 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |